Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical is making progress in its pre-conditional privatization of Shanghai Henlius Biotech by merger, as it continues to liaise with Chinese authorities to fulfill necessary pre-conditions. The company has delayed the dispatch of the Composite Document, now expected by May 2025 or upon pre-condition fulfillment. This move is part of Fosun’s strategic efforts to streamline its operations within the pharmaceutical sector.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
